Document is current

Article History

Received: 9 January 2026

Revised: 2 March 2026

Accepted: 4 March 2026

First Online: 23 March 2026

Declarations

:

: AV, KG, EC, CH, EMM, TD, JE, MS, and EBA declare no disclosures related to this study. JH declares consultant fees for Roche SAS and Eisai SAS. JD declares consultant fees from Eli Lilly, Lilly France, Roche Diagnostics International LTD, Eisai SAS, and Novo Nordisk. ML declares being an investigator or co-investigator for studies by Bayer and Bristol-Myers Squibb laboratories (unpaid), participation in the Eisai Symposium on Behavioural Neurology 2023 (unpaid), and consulting for a brochure on Alzheimer's disease Eisai 2024 (paid). CP declares consulting fees from Eli Lilly, Roche, and Eisai (all paid to the institution); payment or honoraria from Fondation Assistance Publique – Hôpitaux de Paris for a presentation; participation on a data safety monitoring boards or advisory boards for Eli Lilly, Roche, and Eisai; a leadership or fiduciary role in Fondation Vaincre Alzheimer, Association Maladie à corps de Lewy, and France Alzheimer.

: All patients provided oral and written informed consent for participation in the BioCogBank study, a prospective clinical study of neurocognitive disorders and biomarkers (NCT06244875). The BioCogBank study was approved by the ethics committee Comité de Protection des Personnes Est III (2023-A01413-42, 23–10-02) and was conducted in accordance with the principles of the Declaration of Helsinki.